Advanced Search

Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2014 October;80(10) > Minerva Anestesiologica 2014 October;80(10):1135-42



A Journal on Anesthesiology, Resuscitation, Analgesia and Intensive Care

Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,036

Frequency: Monthly

ISSN 0375-9393

Online ISSN 1827-1596


Minerva Anestesiologica 2014 October;80(10):1135-42


Aminoglycosides for life-threatening infections: a plea for an individualized approach using intensive therapeutic drug monitoring

De Waele J. J. 1, De Neve N. 2

1 Department of Critical Care Medicine, Ghent University Hospital, Ghent, Belgium;
2 Department of Anesthesiology and Intensive Care Medicine, O. L. Vrouw Hospital Aalst, Aalst, Belgium

Aminoglycosides are potent antibiotics with a renewed interest due to the increase in multidrug resistant infections. Their use in life-threatening infections ‑ in combination with other antibiotics ‑ has been debated due to the lack of clear outcome benefits. However, based on recent pharmacokinetic-pharmacodynamic studies, conventional dosing may be inefficient in a considerable number of patients, which could preclude the efficiency of this potent drug class. Toxicity on the other hand remains a concern, with nephrotoxicity as the most relevant negative effect in the critically ill. Short term, intensively monitored treatment strategies — with monitoring both peak and trough levels — may increase efficacy as well as reduce toxicity in the critically ill patient.

language: English


top of page